Mottola Frank

Frank Mottola, Senior Vice President and Chief Technology Operations Officer, has demonstrated a clear selling bias in his transactions involving Supernus Pharmaceuticals (SUPN), the only company in which he has reported insider activity. Over 26 filings, his total sales amount to $2.18 million, significantly outweighing his $955,220 in purchases. The most substantial sales occurred in late 2025, including a $757,050 transaction on December 19, 2025, followed by additional sales of $251,100 and $229,350 earlier that year. More recently, between February and March 2026, Mottola executed five smaller sales totaling approximately $318,000, with the largest being a $98,130.89 transaction on March 6, 2026, and an $87,073.95 sale on March 9, 2026. The pattern suggests a consistent reduction in his SUPN holdings, with no recent purchases reported. Many of the transactions in early 2026 appear to be routine dispositions, as indicated by the "F" (tax liability) and "S" (sale) codes, while the larger 2025 sales were likely tied to option exercises ("M" codes). The absence of any buy transactions since at least August 2025 reinforces the trend of divestment rather than accumulation. While the sales vary in size, the overall direction points to a gradual unwinding of his position in SUPN over the past several months.